Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prazosin and CSF Biomarkers in mTBI
NCT03221751Phase 4Terminated
- Sponsor
- VA Office of Research & Development
- Start
- Dec 2016
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Alzheimer's disease (AD) and chronic traumatic encephalopathy (CTE) comparing Prazosin with Placebo (2 arms). Primary endpoints: Change in CSF Total-tau From Baseline to End of Study at 10 weeks, Change in p-tau181 From Baseline to End of Study at 10 weeks and 1 more. Started Dec 2016; status: terminated.
02
Drugs
prazosin
03
Conditions
Alzheimer's disease (AD)chronic traumatic encephalopathy (CTE)
Beyond the preview
Go deeper on NCT03221751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03221751.